IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.135,86 +642,09 (+1,10%)
Ultragenyx Pharmaceutical Inc. (RARE)
Después del cierre:
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 1276
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1,46M | 1,27M | 1960 |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 184,81k | N/A | 1978 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 846,74k | N/A | 1978 |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 860,05k | N/A | 1966 |
| Mr. Erik Harris | Executive VP & Chief Commercial Officer | 878,77k | N/A | 1971 |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | N/A | 1971 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | N/A | N/A | 1965 |
| Mr. Thomas R. Kassberg | Chief Business Officer & Executive VP | 714,84k | N/A | 1960 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | N/A | N/A | 1965 |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and EVP of Gene Therapy Research & Development | 331,33k | N/A | 1965 |
Descripción
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Gobierno corporativo
El ISS Governance QualityScore de Ultragenyx Pharmaceutical Inc., a día 1 de mayo de 2024, es 4. Las puntuaciones base son Auditoría: 2; Tablero: 2; Derechos de los accionistas: 7; Compensación: 5.
